Vertex Pharmaceuticals Inc (NAS:VRTX)
$ 465.73 -2.4 (-0.51%) Market Cap: 119.94 Bil Enterprise Value: 115.74 Bil PE Ratio: 0 PB Ratio: 7.68 GF Score: 93/100

Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 04:15PM GMT
Release Date Price: $419.12 (+0.63%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Hey, good morning, everyone. We're going to get started. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, continuing the 42nd Annual Healthcare Conference this morning with Vertex. I'm joined by the company's CEO, Reshma Kewalramani. After the session, you don't have to switch rooms. We're going to go straight into Q&A. You're welcome to ask questions in the room. You can submit them to me on this iPad through the portal or you can listen to me ask questions. So with that, let me turn it over to Reshma for the presentation.

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Thanks, Jess. Jess, thank you very much. Thank you to JPMorgan. Good morning all. It's great to be here in San Francisco in person to kick off the year. On behalf of the entire Vertex team, I'm delighted to be here with you to give you an update on the CF business, our diversification into new disease areas with the near-term approval of casgevy and many more near

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot